Skip to content

Deep Learning With MRI-based Multimodal-data Fusion Enhanced Postoperative Risk Stratification of Breast Cancer

Deep Learning With MRI-based Multimodal-data Fusion Enhanced Postoperative Risk Stratification of Breast Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06546072
Enrollment
1199
Registered
2024-08-09
Start date
2011-03-23
Completion date
2021-12-06
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

deep learning

Brief summary

Breast cancer poses a significant global health challenge, especially among women, with high rates of recurrence and distant spread despite early interventions. The timely identification of metastasis risk and accurate prediction of treatment strategies are critical for improving prognosis. However, the complex heterogeneity of breast tumors presents challenges in precise prognosis prediction. Therefore, the development of innovative methods for tumor segmentation and prognosis assessment is essential. The research conducted is a multicenter study that enrolled 1,199 non-metastatic breast cancer patients from four independent centers. Our study leverages the advancements in artificial intelligence (AI) to address this challenge. This study is the first successful application of MRI-based multimodal prediction system to precisely identify the risk of postoperative recurrence in breast cancer patients.

Interventions

OTHERMRI

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed stage I-III invasive BC * Age ≥ 18 years * The patient having undergone surgery * The existence of MRI scans

Exclusion criteria

* Lacked pathological results * Had other, simultaneous malignancies * Had MR imaging issues were excluded

Design outcomes

Primary

MeasureTime frameDescription
DFSThe time from surgery to tumor recurrence, including local and/or distant recurrence, disease progression, or death, assessed up to 100 months.Disease-free survival

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026